Last reviewed · How we verify
Sacrosidase Oral Solution
At a glance
| Generic name | Sacrosidase Oral Solution |
|---|---|
| Also known as | sacrosidase |
| Sponsor | QOL Medical, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels (PHASE4)
- Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance (PHASE2)
- A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sacrosidase Oral Solution CI brief — competitive landscape report
- Sacrosidase Oral Solution updates RSS · CI watch RSS
- QOL Medical, LLC portfolio CI